Objective
M.tuberculosis remains the leading cause of death worldwide from an infectious agent and is responsible for nearly three million deaths every year. About one-third of the world population is infected with M. tuberculosis, 10 % of which will develop the disease at some point in their lives. Currently available antibiotics are completely ineffective against persistent bacteria The aim of our project is to solve the 3-D structure of several sterilising drug targets, some of which have been identified by us recently. This would lead to the development of totally novel antibiotics, with completely new modes of action, which are active against stationary phase persistent Mycobacterium tuberculosis. These antibiotics will shorten the duration of chemotherapy and/or synergies with existing antibiotics in humans by reducing bacterial subpopulations, which are tolerant to conventional antimicrobials and thus control reactivation of TB.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- natural sciencesbiological sciencesmicrobiologybacteriology
- medical and health sciencesclinical medicinepneumologytuberculosis
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
You need to log in or register to use this function
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
38124 BRAUNSCHWEIG
Germany